The average one-year price target for DexCom (NasdaqGS:DXCM) has been revised to $88.30 / share. This is a decrease of 13.54% ...

What a brutal six months it’s been for DexCom. The stock has dropped 32.6% and now trades at $58.63, rattling many ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...

NEW YORK - November 18, 2025 ( NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (NASDAQ: DXCM) of a class action securities lawsuit.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights: 1 Third ...

A Raymond James analyst cut his price target on the specialty medical device maker. It was the second such price target cut so far this month. Raymond James prognosticator Jayson Bedford was the ...

Dexcom Share, a cradle device that will allow users to send data from a Dexcom continuous glucose monitor to multiple smartphones, has received 510(k) clearance from the FDA. The system is designed to ...

Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in ...